Docking studies for multi-target drugs

Current Drug Targets

Volumn 18, Issue 5, 2017, Pages 592-604

  Scotti, Luciana ^a   Mendonça Júnior, Francisco J B ^b   Ishiki, Hamilton M ^c   Ribeiro, Frederico F ^d   Singla, Rajeev K ^e   Barbosa Filho, José M ^a   Da Silva, Marcelo S ^a   Scotti, Marcus T ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^b STATE UNIVERSITY OF PARAÍBA   (Brazil)

^c UNIVERSIDADE DO OESTE PAULISTA UNOESTE   (Brazil)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^e NETAJI SUBHAS INSTITUTE OF TECHNOLOGY   (India)

Author keywords

CADD; Diseases; Docking; Multi target drugs; Network; Polypharmacology; Receptor

Indexed keywords

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; CHINESE MEDICINE; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG TARGETING; FIBROSING ALVEOLITIS; GENE MUTATION; HUMAN; MOLECULAR DOCKING; NEOPLASM; NONHUMAN; REVIEW; ANIMAL; BIOLOGY; COMPUTER AIDED DESIGN; POLYPHARMACOLOGY; PROCEDURES; THEORETICAL MODEL;

ANIMALS; COMPUTATIONAL BIOLOGY; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; MODELS, THEORETICAL; MOLECULAR DOCKING SIMULATION; POLYPHARMACOLOGY;

EID: 85015640850     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150825111818     Document Type: Review

References (155)

1. Dias KS, Viegas CJr. Multi-target directed drugs: a modern approach for design of new drugs for the treatment of alzheimer's disease. Curr Neuropharmacol 2014; 12: 239-55.
2. Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr Drug Targets 2011; 12(1): 122-32.
3. Pierce G. Should we clean up the reputation of “dirty drugs”? Can J Physiol Pharmacol 2012; 90(10): 1333-4.
4. Koeberle A, Werz O. Multi-target approach for natural products in inflammation. Drug Discov Today [Internet]. Elsevier Ltd; 2014; 19(12): 1871-82. Available from:http://dx.doi.org/10.1016/j.drudis.2014.08.006.
5. Agis-torres A, Söllhuber M, Fernandez M, Sanchez-Montero JM. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer’ s disease. Curr Neuropharmacol 2014; 12: 2-36.
6. Bajda M, Guzior N, Ignasik M, Malawska B. Multi-target-directed ligands in Alzheimer’s disease treatment. Curr Med Chem 2011; 18: 4949-75.
7. Bolognesi LM. Multi-Target-Directed Ligands as Innovative Tools to Combat Trypanosomatid Diseases. Curr Top Med Chem 2011; 11(22): 2824-33.
8. Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 2006; 149(8): 998-1012.
9. Mancini F, Naldi M, Cavrini V, Andrisano V. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Anal Bioanal Chem 2007; 388(5-6): 1175-83.
10. Aprile G, MacErelli M, Giuliani F. Regorafenib for gastrointestinal malignancies: From preclinical data to clinical results of a novel multi-target inhibitor. BioDrugs 2013; 27(3): 213-24.
11. Huang S, Kauffman S. How to escape the cancer attractor: Rationale and limitations of multi-target drugs. Semin Cancer Biol [Inter-net]. Elsevier Ltd; 2013; 23(4): 270-8. Available from: http://dx.doi.org/10.1016/j.semcancer.2013.06.003
12. Gyurkó DM, Veres DV, Módos D, Lenti K, Korcsmáros T, Cser-mely P. Adaptation and learning of molecular networks as a description of cancer development at the systems-level: Potential use in anti-cancer therapies. Semin Cancer Bio. 2013; 23(4): 262-9.
13. O'Boyle NM, Meegan MJ. Designed Multiple Ligands for Cancer Therapy. Curr Med Chem 2011; 18(31): 4722-37.
14. Limaverde-Sousa G, Sternberg C, Ferreira CG. Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev [Internet]. Elsevier Ltd; 2014;40(4):548-57. Available from: http://dx.doi.org/10.1016/j.ctrv.2013.11.009.
15. Fallahi P, Ferrari SM, Vita R, et al. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Expert Opin Drug Saf 2014; 13(6): 723-33.
16. Ku X, Heinzmeir S, Helm D, Medard G, Kuster B. New Affinity Probe Targeting VEGF Receptors for Kinase Inhibitor Selectivity Profiling by Chemical Proteomics. J Proteome Res 2014; 13(5): 2445-52.
17. Bronte G, Bronte E, Novo G, et al. Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opin Drug Saf 2015; 14(2): 253-67.
18. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013; 123(8): 3190-200.
19. Navarro M, Gabbiani C, Messori L, Gambino D. Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: Recent achievements and perspectives. Drug Discov Today [Internet]. Elsevier Ltd; 2010;15(23-24):1070-8. Available from: http://dx.doi.org/10.1016/j.drudis.2010.10.005
20. Otero L, Vieites M, Boiani L, et al. Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. J Med Chem 2006; 49(11): 3322-31.
21. Vieites M, Otero L, Santos D, et al. Platinum(II) metal complexes as potential anti-Trypanosoma cruzi agents. J Inorg Biochem 2008; 102(5-6): 1033-43.
22. Iniguez E, Sánchez A, Vasquez MA, et al. Metal-drug synergy: New ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells. J Biol Inorg Chem 2013; 18(7): 779-90.
23. Anighoro A, Stumpfe D, Heikamp K, et al. Computational Polypharmacology Analysis of the Heat Shock Protein 90 Interactome. J Chem Inf Model 2015; 55(3): 676-86.
24. Mendonça Junior FJB, Scotti L, Botelho SPS, Ishiki HM, Silma MS, Scotti MT. Benzo- and Thienobenzo- Diazepines Multi-target drugs for CNS disordes. Mini-Reviews Med Chem 2015; 15: 2630-647.
25. Garuti L, Roberti M, Bottegoni G. Multi-Kinase Inhibitors. Curr Med Chem 2015; 22(6): 695-712.
26. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. Drug-target network. Nat Biotechnol 2007; 25(10): 1119-26.
27. Hecht D, Fogel GB. Computational Intelligence Methods for Docking Scores. Curr Comput-Aided Drug Des 2009; 5(1): 56-68.
28. Lavecchia A, Di Giovanni C. Virtual Screening Strategies in Drug Discovery: A Critical Review. Curr Med Chem 2013; 20(23): 2839-60.
29. De Azevedo WF. MolDock Applied to Structure-Based Virtual Screening. Curr Drug Targets 2010; 11(3): 327-34.
30. Ogungbe IV, Setzer WN. Comparative Molecular Docking of Antitrypanosomal Natural Products into Multiple Trypanosoma brucei Drug Targets. Molecules 2009; 14(4): 1513-36.
31. Xu J, Hagler A. Chemoinformatics and drug discovery. Molecules 2002; 7(8): 566-600.
32. Guimaraes MC, Silva DG, da Mota EG, da Cunha EFF, Freitas MP. Computer-assisted design of dual-target anti-HIV-1 compounds. Med Chem Res 2014; 23(3): 1548-58.
33. Jian-guo W, Yan-yan W, Zi-lv Z, Bin Y. Herbal Medicine in the Treatment of Alzheimer’s Disease. Curr Med Chem Anticancer Agents 2002; 2(2): 209-14.
34. Chang YX, Ge AH, Donnapee S, et al. The multi-targets integrated fingerprinting for screening anti-diabetic compounds from a Chinese medicine Jinqi Jiangtang Tablet. J Ethnopharmacol 2015; 164: 210-22.
35. Jiang P, Sheng YC, Chen YH, Ji LL, Wang ZT. Protection of Flos Lonicerae against acetaminophen-induced liver injury and its mechanism. Environ Toxicol Pharmacol 2014; 38(3): 991-9.
36. Higashino S, Sasaki Y, Giddings JC, et al. Crocetin, a Carotenoid from Gardenia jasminoides Ellis, Protects against Hypertension and Cerebral Thrombogenesis in Stroke-prone Spontaneously Hyper-tensive Rats. Phytother Res 2014; 28(9): 1315-9.
37. Ler MJT, Weathers PJ. Variations in key artemisinic and other metabolites throughout plant development in Artemisia annua L. for potential therapeutic use. Ind Crop Prod 2015; 67: 185-91.
38. Zhang P, Luo HS, Li M, Tan SY. A rtesunate inhibits the growth and induces apoptosis of human gastric cancer cells by downregu-lating COX-2. OncoTargets Ther 2015; 8: 845-54.
39. Zhang XZ, Gu JY, Cao L, et al. Network pharmacology study on the mechanism of traditional Chinese medicine for upper respiratory tract infection. Mol Biosyst 2014; 10(10): 2517-25.
40. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4(11): 682-90.
41. Duijker G, Bertsias A, Symvoulakis EK, et al. Reporting effectiveness of an extract of three traditional Cretan herbs on upper respiratory tract infection: Results from a double-blind randomized controlled trial. J Ethnopharmacol 2015; 163: 157-66.
42. Nazzari E, Torretta S, Pignataro L, Marchisio P, Esposito S. Role of biofilm in children with recurrent upper respiratory tract infections. Eur J Clin Microbiol Infect Dis 2015; 34(3): 421-9.
43. da Silva RC, Mendes GD, Rojas MA, et al. Frequency of viral etiology in symptomatic adult upper respiratory tract infections. Braz J Infect Dis 2015; 19(1): 30-5.
44. Furlong LI. Human diseases through the lens of network biology. Trends Genet 2013; 29(3): 150-9.
45. Nogara PA, Saraiva RD, Bueno DC, et al. Virtual Screening of Acetylcholinesterase Inhibitors Using the Lipinski's Rule of Five and ZINC Databank. Biomed Res Int 2015; 2015: 870389.
46. Zhang XZ, Gu JY, Cao L, et al. Insights into the inhibition and mechanism of compounds against LPS-induced PGE(2) production: a pathway network-based approach and molecular dynamics simulations. Integr Biol 2014; 6(12): 1162-9.
47. Wu DY, Meydani SN. Mechanism of age-associated up-regulation in macrophage PGE(2) synthesis. Brain Behav Immun 2004; 18(6): 487-94.
48. Agard M, Asakrah S, Morici LA. PGE(2) suppression of innate immunity during mucosal bacterial infection. Front Cell Infect Microbiol 2013; 3: 11.
49. Al Bar H, Sobande A, Hussein O, Thiga R, Mushait M. The experience with prostaglandin E2 vaginal tablets for induction of labour in grand and great grand multiparae. A two year review in Saudi Arabia. J Obstet Gynaecol 2000; 20(2): 132-5.
50. Jozwiak M, Rengerink KO, Ten Eikelder MLG, et al. Foley catheter or prostaglandin E2 inserts for induction of labour at term: an open-label randomized controlled trial (PROBAAT-P trial) and systematic review of literature. Eur J Obstet Gynecol Reprod Biol 2013; 170(1): 137-45.
51. Romero A, Caceres M, Arancibia R, et al. Cigarette smoke conden-sate inhibits collagen gel contraction and prostaglandin E-2 production in human gingival fibroblasts. J Periodont Res 2015; 50(3): 371-9.
52. Leclerc JL, Lampert AS, Diller MA, Immergluck JB, Dore S. Prostaglandin E-2 EP2 Receptor Deletion Attenuates Intracerebral Hemorrhage-Induced Brain Injury and Improves Functional Recovery. ASN Neuro 2015; 7(2): 14.
53. Chambrey R, Trepiccione F. Relative Roles of Principal and Inter-calated Cells in the Regulation of Sodium Balance and Blood Pressure. Curr Hypertens Rep 2015; 17(4): 11.
54. Inada T, Hirota K, Shingu K. Intravenous anesthetic propofol suppresses prostaglandin E-2 and cysteinyl leukotriene production and reduces edema formation in arachidonic acid-induced ear inflammation. J Immunotoxicol 2015; 12(3): 261-5.
55. Xiang Z, Sun H, Cai X, Chen D, Zheng X. The study on the material basis and the mechanism for anti-renal interstitial fibrosis e-cacy of rhubarb through integration of metabonomics and network pharmacology. Mol Bio Syst 2015; 11: 1067-78.
56. Yongzheng H. Comprehensive natural products in traditional Chinese medicine. Shanghai: Shanghai scientific &Technical Publishers 2011.
57. Luo F, Gu JY, Chen LR, Xu XJ. Systems pharmacology strategies for anticancer drug discovery based on natural products. Mol Biosyst 2014; 10(7): 1912-7.
58. Beniddir MA, Grellier P, Rasoanaivo P, et al. Diarylheptanoid Glucosides from Pyrostria major and Their Antiprotozoal Activities. Eur J Org Chem 2012(5): 1039-46.
59. Campos HC, da Rocha MD, Viegas FPD, et al. The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinson's Disease. CNS Neurol Disord Drug Targets 2011; 10(2): 239-50.
60. Scotti L, Ferreira EI, da Silva MS, Scotti MT. Chemometric Studies on Natural Products as Potential Inhibitors of the NADH Oxidase from Trypanosoma cruzi Using the VolSurf Approach. Molecules 2010; 15(10): 7363-77.
61. Scotti L, Ishiki H, Mendonca FJB, Da Silva MS, Scotti MT. In-silico Analyses of Natural Products on Leishmania Enzyme Targets. Mini-Rev Med Chem 2015; 15(3): 253-69.
62. Wang BC, Deng J, Gao YM, Zhu LC, He R, Xu YQ. The screening toolbox of bioactive substances from natural products: A review. Fitoterapia 2011; 82(8): 1141-51.
63. Scotti L, Scotti MT, Ishiki H, et al. Prediction of Anticancer Activity of Diterpenes Isolated from the Paraiban Flora through a PLS Model and Molecular Surfaces. Nat Prod Comm 2014; 9(5): 609-12.
64. Scotti L, Mendonca FJB, Moreira DRM, da Silva MS, Pitta IR, Scotti MT. SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review. Curr Top Med Chem 2012; 12(24): 2785-809.
65. Scotti L, Ishiki H, Mendonca FJB, Santos PF, Tavares JF, Silva MS, et al. Theoretical Research into Anticancer Activity of Diterpenes Isolated from the Paraiban Flora. Nat Prod Comm 2014; 9(7): 911-4.
66. Chen XW, Di YM, Zhang J, Zhou ZW, Li CG, Zhou SF. Interaction of Herbal Compounds with Biological Targets: A Case Study with Berberine. Sci World J 2012; 2012: 708292.
67. Schmidt D, Bernat V, Brox R, Tschammer N, Kolb P. Identifying Modulators of CXC Receptors 3 and 4 with Tailored Selectivity using Multi-Target Docking. ACS Chem. Biol 2015; 10: 715-24.
68. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-50.
69. Sørensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-15.
70. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515-20.
71. Endres MJ, Clapham PR, Marsh M, et al. CD4-independent infection by HIV2 is mediated by fusin/CXCR4. Cell 1996; 87: 745-56.
72. Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Naka-nishi Y, Kanda K, Kawada M, Seno H, Taketo MM, Sakai Y. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer 2013; 132: 276-87.
73. Princen K, Hatse S, Vermeire K, et al. Inhibition of Human Immu-nodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist. J Virol 2004; 78: 12996-3006.
74. Sabroe I, Peck MJ, Van Keulen BJ, et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 2000; 275: 25985-92.
75. Ferrer I. Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 2012; 97: 38-51.
76. Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Bioph Acta 2012; 1822: 631-8.
77. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7: 137-52.
78. Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep 2015; 67(2): 195-203.
79. Gold BT. Lifelong bilingualism and neural reserve against Alzheimer's disease: A review of findings and potential mechanisms. Behav Brain Res 2015; 281: 9-15.
80. Scotti L, Bezerra Mendonca Junior FJ, da Silva MS, Pitta IR, Scotti MT. Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review. Lett Drug Des Discov 2014; 11(2): 240-8.
81. Musial A, Bajda M, Malawska B. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr Med Chem 2007; 14: 2654-79.
82. Goedert M, Spillantini MG. A century of Alzheimer´s disease. Science 2006; 314: 777-81.
83. Bolognesi ML, Cavalli A, Valgimigli L, et al. Multi-target-directed drug design strategy: froma dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer´s disease. J Med Chem 2007; 50: 6446-9.
84. Cavalli A, Bolognesi ML, Capsoni S, et al. A small molecule targeting the multi-factorial nature of Alzheimer´s disease. Angew Chem Int Ed 2007; 46: 3689-92.
85. Youdim BM, Buccafusso JJ. Multi-functional drugs for varios CNS targets in the treatment of neurodegenative diseases. Trends Pharmacol Sci 2005; 26: 27-35.
86. Azam F, Amer AM, Abulifa AR, Elzwawi MM. Ginger components as new leads for the design and development of novel multi-targeted anti-Alzheimer's drugs: a computational investigationle. Drug Des Dev Ther 2014; 8: 2045-59.
87. Owens J, Lipinski C. Chris Lipinski discusses life and chemistry after the Rule of Five. Drug Discov Today 2003; 8(1): 12-6.
88. Gonzalez-Naranjo P, Perez-Macias N, Campillo NE, et al. Can-nabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease. Eur J Med Chem 2014; 73: 56-72.
89. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7(2): 88-95.
90. Thomas A, Pertwee RG. The bioassay of cannabinoids using the mouse isolated vas deferens. Methods Mol. Med 2006, 123: 191e207.
91. Wieckowska A, Wieckowski K, Bajda M, et al. Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with beta-amyloid anti-aggregation properties and beneficial effects on memory in vivo. Bioorg Med Chem 2015; 23(10): 2445-57.
92. Jiang CS, Fu Y, Zhang L, et al. Synthesis and biological evaluation of novel marine-derived indole-based 1,2,4-oxadiazoles derivatives as multifunctional neuroprotective agents. Bioorg Med Chem Lett 2015; 25(2): 216-20.
93. Bautista-Aguilera OM, Samadi A, Chioua M, et al. N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a New Cholinesterase and Monoamine Oxidase Dual. J Med Chem 2014; 57(24): 10455-63.
94. Drtinova L, Dobes P, Pohanka M. Low molecular weight precursor applicable for Alzheimer disease drugs synthesis (AChE and BChE inhibition, BACE inhibition, antioxidant properties and in silico modulation). J Appl Biomed 2014; 12(4): 285-90.
95. Klein LC, Passos CD, Moraes AP, et al. Indole Alkaloids and Semisynthetic Indole Derivatives as Multifunctional Scaffolds Aiming the Inhibition of Enzymes Related to Neurodegenerative Diseases - A Focus on Psychotria L. Genus. Curr Top Med Chem 2014; 14(8): 1056-75.
96. Razafimandimbison SG, Taylor CM, Wikstrom N, Pailler T, Khodabandeh A, Bremer B. Phylogeny and generic limits in the sister tribes Psychotrieae and Palicoureeae (Rubiaceae): evolution of schizocarps in psychotria and origins of bacterial leaf nodules of the Malagasy species. Am J Bot 2014; 101(7): 1102-26.
97. Lu QP, Wang JS, Kong LY. Chemical constituents from Psychotria yunnanensis and its chemotaxonomic study. Biochem Syst Ecol 2014; 52: 20-2.
98. Bremer B. A review of molecular phylogenetic studies of Rubiaceae. Ann Mo Bot Gard 2009; 96(1): 4-26.
99. Luo Z, Sheng J, Sun Y, et al. Synthesis and Evaluation of Multi-Target-Directed Ligands against Alzheimer’s Disease Based on the Fusion of Donepezil and Ebselen. J Med Chem 2013; 56: 9089-99.
100. Meena P, Nemaysh V, Khatri M, Manral A, Luthra PM, Tiwari M. Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer’s disease. Bioorg Med Chem 2015; 23: 1135-48.
101. León R, Garcia AG, Marco-Contelles, J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease. Med Res Rev 2013; 33: 139-89.
102. Zhang HY. One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Lett 2005; 579: 5260-4.
103. Luo Z, Sheng J, Sun Y, et al. Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen. J Med Chem 2013; 56: 9089-99.
104. Pudlo M, Luzet V, Ismaïli L, Tomassoli I, Iutzeler A, Refouvelet B. Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer Disease. Bioorg Med Chem 2014; 22: 2496-507.
105. Ezoulin JMM, Shao B, Xia Z, et al. Novel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice. Int J Neuropsychopharmacol 2009; 12: 1409-19.
106. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Sci 1991; 253: 872-9.
107. Chen Y, Sun J, Peng S, Liao H, Zhang Y, Lehmann J. Tacrine-Flurbiprofen Hybrids as Multifunctional Drug Candidates fot the Treatment of Alzheimer´s Disease. Arch Pharm Chem Life Sci 2013; 346: 865-71.
108. Spilovska K, Korabecny J, Kral J, et al. 7-Methoxytacrine-Adamantylamine Heterodimers as Cholinesterase Inhibitors in Alzheimer’s Disease treatment — Synthesis, Biological Evaluation and Molecular Modeling Studies. Molecules 2013; 18: 2397-418.
109. Nicolet Y, Lockbridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003; 278: 41141-7.
110. Nadri H, Pirali-Hamedani M, Moradi A, et al. 5,6-Dimethoxybenzofuran-3-one derivatives: a novel series of dual Acetylcholinesterase/Butyrylcholinesterase inhibitors bearing benzyl pyridinium moiety. DARU J Pharm Sci 2013; 21(15): 1-9.
111. Shi DH, Yan ZQ, Zhang LN, Wang YR, Jiang CP, Wu CH. A Novel 7-O-Modified Genistein Derivative with Acetylcholinesterase Inhibitory Effect, Estrogenic Activity and Neuroprotective Effect. Arch Pharm Res 2012; 35(9): 1645-54.
112. Freed-Pastor WA, Mizuno H, Zhao X, et al. Mutant p53 disrupts mammary tissue architecture via themevalonate pathway. Cell 2012; 148: 244-58.
113. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007; 40: 575-84.
114. Gao J, Liu J, Qiu Y, Chu X, Qiao Y, Li D. Multi-target-directed design, syntheses, and characterization of fluorescent bisphosphonate derivatives as multifunctional enzyme inhibitors in mevalonate pathway. Biochim Biophys Acta 2013; 1830: 3635-42.
115. Bolognesi ML. Polypharmacology in a single drug: multi target drugs. Curr Med Chem 2013; 20: 1639-45.
116. Stiepanovic N, Capdevila J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics 2014; 8: 129-39.
117. Ma XH, Wang R, Tan CY, et al. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. Mol Pharmacol 2010; 7: 1545-60.
118. Porta C, Paglino C, Mosca A. Targeting PI3K/AKT/mTOR signaling in cancer. Front Oncol 2014; 4: 1-11.
119. Saurat T, Buron F, Rodrigues N, et al. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors. J Med Chem 2014; 57: 613-31.
120. Barbey S, Goossens L, Taverne T, et al. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg Med Chem Lett 2002; 12: 779-82.
121. Hibi S, Okamoto Y, Tagami K, et al. Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives. J Med Chem 1994; 37: 3062-70.
122. Chen Z, Wu YR, Liu Y, Yang SJ, Chen YJ, Lai LH. Discovery of dual target inhibitors against cyclooxygenases and leukotriene A(4) hydrolyase. J Med Chem 2011; 54: 3650-60.
123. Wei DG, Jiang XL, Zhou L, et al. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching, J Med Chem 2008; 51: 7882-8.
124. Meng H, Liu Y, Zhai Y, Lai L. Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolas. Eur J Med Chem 2013; 59: 160-7.
125. Jayaraman P, Sakharkar KR, Lim CS, Siddiqi MI, Dhillon SK, Sakharkar MK. Novel phytochemical-antibiotic conjugates as multitarget inhibitors of Pseudomononas aeruginosa GyrB/ParE and DHFR. Drug Design Develop Ther 2013; 7: 449-75.
126. Swaminathan B, Gerner-Smidt P. The epidemiology of human listerosis. Microbes Infect 2007; 9: 1236-43.
127. Nwachukwu N, Orji F, Iheukwumere I, Ekeleme U. Antibiotic resistant environmental isolates of Listeria monocytogenes from anthropogenic lakes in Lokpa-Ukwu Abia State of Nigerria. Australian Journal of Basic and Applied Sciences 2010; 4: 1571-6.
128. Sarangi AN, Lohani M, Aggarwal R. Proteome mining for drug target identification in Listeria monocytogenes strain EGD-e and structure-based virtual screening of a candidate drug target penicillin binding protein 4. J Microbiol Methods 2015; 111: 9-18.
129. Yu CS, Lin CJ, Hwang JK. Predicting subcellular localization of proteins for Gram-negative bacteria by support vector machines based on n-peptide compositions. Protein Sci 2004; 13: 1402-6.
130. Knox C, Law V, Jewison T, et al. DrugBank 3.0: a comprehensive resource for ´omics´ research on drugs. Nucleic Acids Res 2011; 39: D1035-D1041.
131. Jiao X, Sherman BT, Huang W, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics 2012; 28: 1805-6.
132. Kharkar PS, Warrier S, Gaud RS. Reverse docking: a powerful tool for drug repositioning and drug rescue. Future Med Chem 2014; 3: 333-42.
133. Khandouzi N, Shidfar F, Rajab A, Rahideh T, Hosseini P, Taheri MM. The Effects of Ginger on Fasting Blood Sugar, Hemoglobin A1c, Apolipoprotein B, Apolipoprotein A-I and Malondialdehyde in Type 2 Diabetic Patients. Iran J Pharm Res 2015; 14(1): 131-40.
134. Sieri S, Krogh V, Agnoli C, et al. Dietary glycemic index and glycemic load and risk of colorectal cancer: results from the EPIC-Italy study. Int J Cancer 2015; 136(12): 2923-31.
135. Jie Q, Kodithuwakku ND, Yuan X, et al. Anti-allergic and anti-inflammatory properties of a potent histamine H-1 receptor antagonist, desloratadine citrate disodium injection, and its anti-inflammatory mechanism on EA.hy926 endothelial cells. Eur J Pharmacol 2015; 754: 1-10.
136. Puustjarvi V, Strbian D, Tiainen M, Curtze S, Tatlisumak T, Saira-nen T. Recognition of posterior circulation stroke. Acta Neurol Scand 2015; 131(6): 389-93.
137. Gu JY, Luo F, Chen LR, Yuan G, Xu XJ. A systematic study of chemogenomics of carbohydrates. Mol Biosyst 2014; 10(3): 391-7.
138. Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MNDS. Predicting multiple ecotoxicological profiles in agrochemical fungicides: a multi-species chemoinformatic approach. Ecotoxicol Environ Saf 2012; 80: 308-13.
139. Speck-Planche A, Kleandrova VV, Scotti MT. Fragment-based approach for the in silico discovery of multi-target insecticides. Chemometr Intell Lab Syst 2012; 111: 39-45.
140. Speck-Planche A, Cordeiro MNDS. Computer-aided drug design methodologies toward the design of anti-hepatitis C agents. Curr Top Med Chem 2012; 12: 802-13.
141. Garcia I, Fall Y, Gomez G, Gonzalez-Diaz H. First computational chemistry multi-target model for anti-Alzheimer, anti-parasitic, anti-fungi, and anti-bacterial activity of GSK-3 inhibitors in vitro, in vivo, and in different cellular lines. Mol Divers 2011; 15: 561-7.
142. Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MNDS. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis. Comb Chem High Throughput Screen 2012; 15: 666-73.
143. Prado-Prado FJ, Garcia-Mera X, Gonzalez-Diaz H. Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg Med Chem 2010; 18: 2225-31.
144. Speck-Planche A, Cordeiro MNDS. Simultaneous modeling of antimycobacterial activities and ADMET profiles: a chemoinformatic approach to medicinal chemistry. Curr Top Med Chem 2013; 13: 1656-65.
145. Speck-Planche A, Cordeiro MNDS. Simultaneous virtual prediction of anti-Escherichia coli activities and ADMET profiles: A chemoinformatic complementary approach for high-throughput screening. ACS Comb Sci 2014; 16: 78-84.
146. Prado-Prado FJ, Garcia I, Garcia-Mera X, Gonzalez-Diaz H. Entropy multi-target QSAR model for prediction of antiviral drug complex networks. Chemometr Intell Lab Syst 2011; 107: 227-33.
147. Speck-Planche A, Cordeiro MNDS. Chemoinformatics for medicinal chemistry: in silico model to enable the discovery of potent and safer anti-cocci agents. Future Med Chem 2014; 6: 2013-28.
148. Marzaro G, Chilin A, Guiotto A, et al. Using the TOPS-MODE approach to fit multi-target QSAR models for tyrosine kinases inhibitors. Eur J Med Chem 2011; 46: 2185-92.
149. Speck-Planche A, Luan F, Cordeiro MNDS. Abelson tyrosine-protein kinase 1 as principal target for drug discovery against leukemias. Role of the current computer-aided drug design methodologies. Curr Top Med Chem 2012; 12: 2745-62.
150. Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MNDS. Unified multi-target approach for the rational in silico design of anti-bladder cancer agents. Anticancer Agents Med Chem 2013; 13: 791-800.
151. Alonso N, Caamano O, Romero-Duran FJ, et al. Model for High-Throughput Screening of Multi-Target Drugs in Chemical Neuro-sciences; Synthesis, Assay and Theoretic Study of Rasagiline Carbamates. ACS Chem Neurosci 2013; 4: 1393-403.
152. Speck-Planche A, Kleandrova VV. QSAR and molecular docking techniques for the discovery of potent monoamine oxidase B inhibitors: Computer-aided generation of new rasagiline bioisosteres. Curr Top Med Chem 2012; 12: 1734-47.
153. Speck-Planche A, Luan F, Cordeiro MNDS. Discovery of anti-Alzheimer agents: current ligand-based approaches toward the design of acetylcholinesterase inhibitors. Mini Rev Med Chem 2012; 12: 583-91.
154. Luan F, Cordeiro MNDS, Alonso N, et al. TOPS-MODE model of multiplexing neuroprotective effects of drugs and experimental-theoretic study of new 1,3-rasagiline derivatives potentially useful in neurodegenerative diseases. Bioorg Med Chem 2013; 21: 1870-9.
155. Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MNDS. Multi-target inhibitors for proteins associated with Alzheimer: In silico discovery using fragment-based descriptors. Curr Alzheimer Res 2013; 10: 117-24.